Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4RÎą) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4RÎą) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4RÎą, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCNTB
āļāļ·āđāļāļāļĢāļīāļĐāļąāļConnect Biopharma Holdings Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMar 19, 2021
āļāļĩāļāļĩāđāļQuart (Barry D)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ62
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMar 19
āļāļĩāđāļāļĒāļđāđ3580 Carmel Mountain Road, Suite 200
āđāļĄāļ·āļāļSAN DIEGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92130
āđāļāļĢāļĻāļąāļāļāđ18587271040
āđāļ§āđāļāđāļāļāđhttps://www.connectbiopharm.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCNTB
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMar 19, 2021
āļāļĩāļāļĩāđāļQuart (Barry D)
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Ms. Karen J. Wilson, CPA
Independent Director
Ms. Lisa Peraza
Vice President - Finance
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
Mr. Jeff Cohn, J.D.
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
Mr. Raul Collazo, Ph.D.
Vice President - Global Medical Affairs
Vice President - Global Medical Affairs
Mr. David L. Szekeres
President
Dr. Kan Chen, Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Ms. Karen J. Wilson, CPA
Independent Director
Ms. Lisa Peraza
Vice President - Finance
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ